Ken Griffin Adaptimmune Therapeutics PLC Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Citadel Advisors LLC holds 42,800 shares of ADAP stock, worth $41,944. This represents 0.0% of its overall portfolio holdings.
Number of Shares
42,800
Previous 3,399,514
98.74%
Holding current value
$41,944
Previous $2.69 Million
97.5%
% of portfolio
0.0%
Previous 0.0%
Shares
26 transactions
Others Institutions Holding ADAP
# of Institutions
84Shares Held
160MCall Options Held
42.8KPut Options Held
42.1K-
Matrix Capital Management Company, LP Waltham, MA39MShares$38.2 Million0.57% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA27.4MShares$26.9 Million1.23% of portfolio
-
Nea Management Company, LLC Timonium, MD17.1MShares$16.7 Million1.89% of portfolio
-
Baillie Gifford & CO15.9MShares$15.6 Million0.02% of portfolio
-
Baker Bros. Advisors LP New York, NY10.8MShares$10.6 Million0.22% of portfolio
About Adaptimmune Therapeutics PLC
- Ticker ADAP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 163,370,000
- Market Cap $160M
- Description
- Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...